Express Healthcare
Home  »  News  »  Roche announces no anticipated impact of Omicron variant on its cobas and Elecsys assays

Roche announces no anticipated impact of Omicron variant on its cobas and Elecsys assays

0 65
Read Article

The company is taking adequate steps to ensure that our tests perform as expected

Roche Diagnostics has announced that based on company’s global surveillance team’s in silico (computer-based) analyses, the cobas® SARS-CoV-2 is predicted to detect all variants including the Omicron variant (including sub-lineages BA.1 and BA.2).

The company’s statement says, “Based on our assay design, no impact of the variants including Omicron is expected on the Elecsys® Anti-SARS-CoV-2 and Elecsys® SARS-CoV-2 Antigen assays. As new variant strains emerge, we are swiftly taking adequate steps to ensure that our tests perform as expected.”

According to Narendra Varde, Managing Director, Roche Diagnostics India & Neighbouring Markets said, “We continue to monitor the evolution of SARS-CoV-2 variants and remain committed to providing laboratories with high-quality molecular and serology testing solutions that aid in diagnosing affected patients. Our cobas® SARS-CoV-2 assay has been used extensively in the country during the pandemic and continues to remain reliable and useful with the emerging Omicron variant.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image